The strong revenue growth trajectory and FDA acceptance of the sBLA are positive catalysts, but persistent deep losses and a history of post-earnings stock declines suggest caution. Monitor for the PDUFA date in January 2027 and any updates on the planned sBLA submission for the BCG-naive NMIBC trial.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 4 $6.95entry
- T+1 · 3mo ago +4.32%α +4.52% · $7.25
- T+5 · 3mo ago +9.35%α +9.45% · $7.60
- T+20 · 3mo ago +13.24%α +14.48% · $7.87
- T+60 · 20d ago +24.17%α +24.39% · $8.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially, marking the eighth consecutive quarter of growth. The FDA accepted the sBLA for ANKTIVA in BCG-unresponsive NMIBC with a PDUFA date of Jan 6, 2027.
Key Financial Metrics
Key Facts
- Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially from Q1 2026.
- First-half 2026 net product revenue of $94.8M, up 121% YoY.
- FDA accepted sBLA for ANKTIVA in BCG-unresponsive NMIBC with papillary-only disease; PDUFA date Jan 6, 2027.
- GAAP net loss attributable to common stockholders was $230.4M in Q2 2026 vs $92.6M in Q2 2025.
- Adjusted net loss (non-GAAP) was $81.0M in Q2 2026 vs $89.9M in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $357.4M as of June 30, 2026.
- Entered exclusive development and supply agreement with Japan BCG Laboratory for intravesical Tokyo-172 BCG.
- Eighth consecutive quarter of sequential net product revenue growth since ANKTIVA's commercial launch.
Financial Impact
Q2 2026 net product revenue of $50.7M, up 92% YoY; GAAP net loss of $230.4M; adjusted net loss of $81.0M
Risk Factors
- Persistent GAAP and adjusted net losses despite revenue growth.
- High operating expenses (R&D and SG&A) continue to outpace revenue growth.
- Significant non-cash fair value losses on convertible note and warrant liabilities due to stock price increases.
- Historical stock performance shows large declines following prior earnings reports.
- Dependence on successful regulatory approvals and commercial expansion of ANKTIVA.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326110-26-000077 |
| Document: ibrx-20260804.htm | 0001326110-26-000077 |
| Document: 0001326110-26-000077-index-headers.html | 0001326110-26-000077 |
| Document: 0001326110-26-000077-index.html | 0001326110-26-000077 |
| Document: 0001326110-26-000077.txt | 0001326110-26-000077 |
| 8-K Data (Synthetic) | 0001326110-26-000077 |
Track record
11 reports on IBRX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.12% at T+60 after the Apr 9, 2026 report. 2 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
- Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
- Aug 4, 202614w ago 8-K Neutral 5/10 Viewing Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
- Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
- May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
- Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
- Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers